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by interaction with phosphoinositols. Ubiquitination of cargo 
proteins is so far the only known determinant for ESCRT-
dependent sorting into the extracellular vesicle pathway. Our 
study reveals a function of SUMO protein modification as a 
Ubiquitin-independent ESCRT sorting signal, regulating the 
extracellular vesicle release of α-Synuclein. We deciphered 
in detail the molecular mechanism which directs α-Synuclein 
into extracellular vesicles which is of highest relevance for 
the understanding of Parkinson’s disease pathogenesis and 
progression at the molecular level. We furthermore propose 
that sumo-dependent sorting constitutes a mechanism with 
more general implications for cell biology.
Abstract Extracellular α-Synuclein has been implicated 
in interneuronal propagation of disease pathology in Parkin-
son’s Disease. How α-Synuclein is released into the extracel-
lular space is still unclear. Here, we show that α-Synuclein 
is present in extracellular vesicles in the central nervous 
system. We find that sorting of α-Synuclein in extracellular 
vesicles is regulated by sumoylation and that sumoylation 
acts as a sorting factor for targeting of both, cytosolic and 
transmembrane proteins, to extracellular vesicles. We pro-
vide evidence that the SUMO-dependent sorting utilizes the 
endosomal sorting complex required for transport (ESCRT) 
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Introduction
Extracellular vesicles of 40–100 nm in diameter can either 
be derived from the multivesicular endosome (MVE) 
(exosomes) or shedded from the plasma membrane 
(microvesicles). Both are involved in the release of toxic 
cellular content and intercellular transfer of proteins, lipids 
and RNA, and are referred to jointly as extracellular vesi-
cles (EV) [20, 26, 37, 42, 56, 58, 64, 71].
Sorting into extracellular vesicles is regulated by bind-
ing of proteins to the ESCRT complex (endosomal sorting 
complex required for transport) or by ESCRT-independent 
pathways [61]. Several of the ESCRT machinery’s four 
multimeric subunits bind to ubiquitinated proteins for their 
subsequent delivery to sites of vesicle formation and extra-
cellular vesicle release. Hepatocyte growth factor-regulated 
tyrosine kinase substrate (HRS) protein, TSG101 and 
Vps36, which are components of ESCRT-0, -I and -II com-
plexes, respectively, contain Ubiquitin-binding domains for 
recruitment of ubiquitinated membrane cargo into extracel-
lular vesicles. However, recent data indicate that ubiquit-
ination of membrane proteins may not be the only determi-
nant for ESCRT interaction. ESCRT-dependent sorting to 
lysosomes has been reported for several non-ubiquitinated 
proteins [e.g. the T cell co-receptor CD4 and the delta 
opiod receptor (DOR)] [59]. It is not known whether this 
represents a truly Ubiquitin-independent protein ESCRT 
interaction or if these cargoes might associate with ubiq-
uitinated interaction partners, which mediate Ubiquitin-
dependent sorting to the ESCRT machinery. It therefore 
remains unclear whether sorting determinants exist for 
Ubiquitin-independent sorting into the canonical ESCRT 
pathway.
Posttranslational attachment of SUMO (small Ubiq-
uitin like modifier) to proteins plays an important role 
in the regulation of protein–protein interactions, ena-
bling or inhibiting protein binding [22]. Sumoylated 
heterogeneous nuclear ribonucleoprotein A2B1 (hnRN-
PA2B1) interacts with short specific miRNA motifs 
and controls their loading into extracellular vesicles. 
Interestingly, hnRNPa2B1 in extracellular vesicles is 
sumoylated [73].
We examined the function of posttranslational 
sumoylation as a possible mediator of ESCRT interac-
tion and thereby as a sorting factor for protein release 
with extracellular vesicles. Here, we show that sumoyla-
tion of proteins can mediate their ESCRT-dependent 
sorting into extracellular vesicles. We demonstrate 
that SUMO is recruited to ESCRT formation sites by 
interaction with phosphoinositols and requires ESCRT 
subunits Tsg101, VPS4 and the ESCRT-associated pro-
tein Alix.
Futhermore, we provide evidence that release of the 
cytosolic protein α-Synuclein within extracellular vesi-
cles is SUMO-dependent. α-Synuclein is the major con-
stituent of intracellular pathological aggregates in Par-
kinson’s disease (PD) and dementia with Lewy bodies 
(DLB). The progression of α-Synuclein pathology in PD 
seems to follow a stereotypical anatomical path through 
the brain [9]. This, together with the emergence of aggre-
gated α-Synuclein in transplanted embryonic nigral cells 
in PD patients and cell to cell transfer of α-Synuclein in 
mouse brain and cell culture leads to the assumption of 
interneuronal spreading of disease pathology [13, 14, 
27, 44]. α-Synuclein can be isolated with extracellu-
lar vesicles from cell culture media [2, 16, 28, 41]. We 
have shown that vesicular α-Synuclein may be internal-
ized more efficiently by recipient cells than the free pro-
tein and induce greater toxicity [12]. Therefore, transfer 
of α-Synuclein by extracellular vesicles might play an 
important role in synucleinopathies. Here, we provide 
evidence that α-Synuclein is present in extracellular 
vesicles from human cerebrospinal fluid and identify 
SUMO as a regulator of its sorting to the extracellular 
vesicle pathway and possibly interneuronal spreading of 
α-Synuclein pathology.
Materials and methods
Reagents
Primary antibodies were: mouse monoclonal antibod-
ies against Myc clone 9E10 (Sigma), Flotillin-2 (BD 
Biosciences), α-Synuclein (Invitrogen), Alix (BD Bio-
sciences), TSG101 (GeneTex Inc., Irvine, CA, USA), 
CD63 (BD Biosciences), 6E10 anti-APP (Signet), 
GAPDH clone 6C5 (Abcam), rabbit anti-Glutamate 
Receptor GluR2/3 (Chemicon), rabbit anti-Glutamate 
Receptor GluR1 (Chemicon), rabbit anti-Calnexin (Stress-
Gene), rabbit anti-GFP (Invitrogen), rabbit anti-Integrin 
β5 (Millipore), rabbit anti-UBC9 (Santa Cruz), and rat 
anti-LAMP1 (1D4B) (Santa Cruz). SUMO-2 antibody 
was kindly provided by F. Melchior (Heidelberg, ZMBH, 
Germany) [5]. Secondary antibodies were obtained from 
Dianova and Invitrogen.
Plasmids and siRNA
The following plasmids were used: pEYFP-N1 (Clontech, 
Mountain View USA), Rab5Q79L GFP (M. Zerial, MPI-
CBG, Dresden), pcDNA3 ∆N-α-Synuclein lacking the 
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residues 2–19 was provided by H. Karube, Dept. of Neurol-
ogy, Yamagata, Japan [34], pcDNA3 Myc-SUMO-2, pcDNA3 
Myc-SUMO-2 ∆GG, pEYFP SUMO-1, pEYFP SUMO-1 
∆GG (a C-terminal deletion mutant that cannot be con-
jugated), pcDNA3 Myc-α-Synuclein, pcDNA3 Myc-α-
Synuclein 2KR (bearing the double mutation K96R K102R), 
pcDNA3 Myc-α-Synuclein 2AA (D98A E104A) [38], 
pTE1E2S1 (which codes for the expression of SUMO-1 and 
the E1 and E2 enzymes of the sumoylation pathway [70]), 
pT7.7 encoding for human wild-type α-Synuclein (courtesy 
of the P. Lansbury laboratory, Harvard Medical School, Cam-
bridge, MA). Fusion constructs α-Synuclein hGLuc1 (S1) and 
α-Synuclein hGLuc2 (S2) were generated as described previ-
ously [51]. SUMO-2-luciferase construct (SUMO-2-S3) was 
created by cloning the amino-terminal fragment of humanized 
Gaussia Luciferase including the same linker as used in S2 into 
BamHI/EcoRI sites of pcDNA3. SUMO-2 was subsequently 
subcloned into EcoRI/XhoI sites. PcDNA3 Myc-α-Synuclein-
SUMO-2 ∆GG, pcDNA3 GFP-SUMO-2 ∆GG, pcDNA3 
GFP-Ubiquitin ∆GG were cloned as described below. Further 
plasmids used were pR4 PLP-Myc, pcDNA3 MLV-Gag-GFP 
(Addgene Plasmid 1813, W. Mothes, Yale University School 
of Medicine), and GFP-VPS4 (E233Q) (P. Woodman, Univer-
sity of Manchester, UK). PcDNA3 GFP-SUMO-2 ∆GG SIM 
(with the triple mutation Q30A F31A I33A) was generated by 
site-directed mutagenesis according to the manufacturer’s pro-
tocol (Quick Change site-directed mutagenesis kit, Stratagene, 
CA, USA). pShuttleCMV GFP-APPsw was kindly provided 
by Patrick Keller (Max-Planck-Institute for Molecular Cell 
Biology and Genetics, Dresden, Germany). SUMO-2 cDNA 
(NM_006936.2) was amplified by PCR using the primers 
(5′–3′) fwTCATCAGCGGCCGCGATGTCCGAGGAGAA 
and rev AGCAGCAGACGGCAGCGTAGTCTAGAAAA 
AAA thereby eliminating the nucleotides that encode the 
C-terminal diglycine motif (named SUMO-2 ∆GG). SUMO-2 
∆GG was introduced 3′ terminally of GFP-APPsw via NotI 
and XbaI restriction sites including a linker of 15 nucleotides 
between APPsw and SUMO-2 ∆GG. For each fusion con-
struct, three PCR reactions were performed. The first PCR 
reaction was setup for the 5′-part; the second PCR reaction for 
the 3′ part of the construct. The PCR products of both reac-
tions were combined within the third PCR reaction using 
the outer primers only. PCR primers for the amplification of 
SUMO-2 (NM_006936.2) and Ubiquitin (NM_021009.5) 
were designed to eliminate the nucleotides that encode the 
C-terminal diglycine motif (named SUMO-2 ∆GG and Ubiq-
uitin ∆GG) and to create a short linker between both con-
structs that were fused. The product of the third PCR reac-
tion was cloned via HindIII and XhoI restriction sites into the 
pcDNA3 vector (Life Technologies, Darmstadt, Germany). 
pcDNA 3 Myc-SUMO2 cleft: SUMO2 cDNA with deletion 
of the C-terminal GG and the mutations Q30A, F31A, K32A, 
I33A, L42A, and Y46A was cloned into pcDNA 3 Myc vector 
via BamHI and XhoI restriction sites. SUMO2 cDNA with 
deletions of the C-terminal GG and the mutations H16A, 
Q30A, F31A, K32A, I33A, H36A, L42A, Y46A, and D62A 
(cleft + loop) and Q30A,F31A,K32A,I33A,L42A,Y46A 
(cleft) were cloned into pcDNA 3 Myc vector via BamHI 
and XhoI restriction sites. The following primer pairs (5′–3′) 
were used for the various constructs: GFP-Ubiquitin ∆GG: 
GFP fw ACCCAAGCTTATGGTGAGCAA, rev ATG-
GACGAGCTGTACAAGGCAGCGATGCAGATCTT; 
Ubiquitin fw TACAAGGCAGCGATGCAGATCTTCGTG 
AA, rev ACCTGGTCCTTCGTCTCAGAGCAGCGTAGC 
TCGAGTTT; GFP-SUMO-2 ∆GG: GFP fw ACCCAA 
GCTTATGGTGAGCAA, rev ATGGACGAGCTGTACA 
AGGCAGCGATGTCCGA; SUMO-2 fw AGCTGTAC 
AAGGCAGCGATGTCCGAGGAGAAGCCC, rev AGCA 
G C A G A C G G C A G C G TA G C T C G A G A A A A ; 
α-Synuclein-SUMO-2 ∆GG: syn fw ATCTGAAGCTT 
ATGGATGTATTCAT, rev TACGAACCTGAAGCCGCAG 
CGATGTCCGA; SUMO-2: fw AAGCCGCAGCGATGT 
CCGAGGAGAAGCCC, rev AGACGGCAGCGTAGCTCG 
AGAAA. The following siRNAs from Qiagen GmbH, Ger-
many, were used: TSG101: sense sequence 5′-CUGUAUA 
AACAGAUUCUAAdTdT-3′, antisense sequence 5′-UUAG 
AAUCUGUUUAUACAGdTdT-3′; Alix: sense sequence 
5′-GAACCUGGAUAAUGAUGAAdTdT-3′, antisense 
sequence 5′- UUCAUCAUUAUCCAGGUUCdTdT-3′. The 
UBC9 siRNA from Dharmacon was CAAAAAAUCCCGA 
UGGCACUU sense sequence, GUGCCAUCGGGAU 
UUUUUGUU antisense sequence.
Cell culture, transfection and siRNA delivery
The oligodendroglial cell line Oli-neu was provided by 
J. Trotter, University of Mainz, Germany, and cultured as 
described [19]. Mouse neuroblastoma N2a cells were main-
tained as described in [55]. Both, Oli-neu and N2a cells 
were plated on glass coverslips or 10-cm plastic dishes and 
transfected with TransIT (Mirus Bio LLC, Madison, WI, 
USA) according to the manufacturer’s protocol. siRNA was 
delivered to N2a cells by Oligofectamine (Invitrogen) and 
cells were transfected 36 h later with the different plasmids, 
followed by medium exchange after 8 h and collection of 
extracellular vesicles. As a control, cells were mock trans-
fected with oligofectamine reagent in the absence of siRNA.
Primary cortical neurons were prepared from E16 
NMRI mouse embryos and cultured on poly-lysine-coated 
glass coverslips or plastic dishes in serum-free MEM sup-
plemented with B27 (Invitrogen). Infection with adeno-
virus-associated virus (AAV) 6 encoding either human 
α-Synuclein wild type or α-Synuclein 2KR was performed 
between days 3 and 4 in vitro. Medium was changed on 
day 6 and extracellular vesicles were prepared on day 7, 
16 h after medium exchange.
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Luciferase activity assay
Luciferase activity assay in extracellular vesicles α-Synuclein 
and SUMO-2-luciferase constructs [α-Synuclein fused to 
full-length gaussia luciferase (syn phGluc); C- or N-termi-
nal fragments of split phGluc fused to α-Synuclein (syn-S2) 
or SUMO-2 (SUMO-2-S3)] were transfected into HEK293 
cells in 10-cm dishes. 16 h after transfection, cells were 
washed with PBS and replaced with serum- and phenol-red 
free media. After 48 h, medium was collected and extra-
cellular vesicles were prepared as described below. Cells 
were washed with PBS and lysed in PBS using sonication. 
Luciferase activity from protein complementation was meas-
ured using same amounts of total protein of cell lysates and 
extracellular vesicle fractions in an automated plate reader 
at 480 nm following the addition of the cell permeable sub-
strate, coelenterazine (40 μM; PJK GmbH, Kleinbittersdorf, 
Germany) with a signal integration time of 2 s.
Immunofluorescence stainings
Immunofluorescence stainings were performed according 
to standard protocols. Images were taken with a laser scan-
ning microscope (Leica SP2, Leica, Mannheim, Germany) 
with a 63 oil plan-apochromat objective.
Virus production
Virus production rAAV6 were used to express α-Synuclein 
wild type and α-Synuclein 2KR (K96R and K102R) under 
the neuron-specific human Synapsin 1 (hSyn1) promotor 
[40]. Virus production was performed as described [38]. 
In brief, vectors were propagated in HEK 293 T cells 
together with the pDP6 helper plasmid. Virus particles 
were purified by iodixanol step purification, followed by 
heparin affinity chromatography with 1 ml HiTrap Hepa-
rin QFF columns (GE Healthcare). Virus particles were 
desalted by dialysis against PBS and titrated by quantita-
tive PCR.
Purification of extracellular vesicles
Extracellular vesicles were isolated as described previ-
ously [65]. Cells were grown on plastic dishes. 8 h after 
transfection, cells were washed three times in phosphate-
buffered saline (PBS) and incubated in serum-free DMEM 
for 16 h. Culture medium was then collected and the super-
natants were subjected to subsequent centrifugation steps 
performed at 4 °C: 3500×g 10 min, 2 times 4500×g for 
10 min, 10,000×g for 30 min and 100,000×g with a TLA 
100.3 rotor (Beckman-Coulter, k-factor 60.6) for 60 min. 
The 100,000×g pellet was washed once with PBS before 
resuspension in sample buffer. To quantify extracellular 
vesicle release, protein parent cell lysates were scraped into 
1 % CHAPS, 5 mM EDTA, 50 mM Tris–HCl, pH 8.0 lysis 
buffer and extracellular vesicle fractions as well as post-
nuclear supernatants of the cell lysates were subjected to 
Western blotting. The ratio of extracellular vesicle protein 
versus cellular protein levels was calculated after scanning 
the blots followed by Image J analysis.
Extracellular vesicles from human cerebrospinal fluid 
for Western blot analysis were prepared from 5 ml of cer-
ebrospinal fluid after the written informed consent was 
given. Analysis of patient cerebrospinal fluid was approved 
by the ethical committee of the Medical Faculty, University 
Medicine Goettingen (IRB 02/05/09).
Sucrose gradient ultracentrifugation
A 100,000×g pellet containing extracellular vesicles was 
prepared as described above and resuspended in 400 μl of 
0.25 M sucrose in 10 mM HEPES, pH 7.4 and layered on 
top of the discontinuous sucrose density gradient consist-
ing of 8 fractions from 0.25 to 2.5 M sucrose. The gradient 
was centrifuged for 16 h at 200,000×g with a 60Ti rotor 
(Beckman-Coulter, k-factor 80.1) or SW41 Ti rotor (Beck-
man-Coulter, k-factor 124), and fractions were recovered 
and centrifuged at 100,000×g after dilution in PBS for 1 h, 
followed by resuspension of the resulting pellet in sample 
buffer and Western blot analysis.
Nanoparticle tracking analysis (NTA)
Cell culture supernatants were centrifuged at 3500×g to 
remove cellular debris. The supernatant was diluted 1:1 in 
PBS (Gibco) and subjected to a NanoSight LM14 instru-
ment equipped with a 532-nm laser (NanoSight Ltd., 
Amesbury, UK). Samples were measured in triplicates for 
30 s. Particle numbers were analysed with the Nanoparticle 
Tracking Analysis (NTA) 2.3 software.
Single particle fluorescence assay for vesicle‑binding 
properties of sumoylated and non‑sumoylated 
α‑Synuclein
Expression and purification of α-Synuclein and sumoylated 
α-Synuclein was performed as described previously [38]. 
Fluorescent labelling with Alexa Fluor-647-O-succin-
imidylester (Molecular Probes, USA) was performed as 
described [23]. Green-labelled small unilamellar dipalmi-
toyl-sn-glycero-3-phospho-choline lipid vesicles (DPPC-
SUV) were generated as described [31]. Fluorescence 
correlation spectroscopy (FCS) and scanning for intensely 
fluorescent targets (SIFTs) measurements for the quantifi-
cation of α-Synuclein vesicle binding were carried out on 
an Insight Reader (Evotec-Technologies) with dual colour 
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excitation at 488 and 633 nm as described before [31]. 
All measurements were performed after incubation of 
DPPC-SUV with labelled α-Synuclein for at least 30 min. 
Measurements under equilibrium conditions were per-
formed >2 h after addition of unlabelled non-sumoylated 
α-Synuclein. Data from at least three parallel samples were 
recorded for each experimental group.
Electron microscopy
Extracellular vesicles were prepared from cerebrospi-
nal fluid and culture medium as described above. The 
100,000×g pellet was fixed with 4 % paraformaldehyde 
and was adsorbed to glow-discharged Formvar-carbon-
coated copper grids by floating the grid for 10 min on 5 μl 
droplets on Parafilm. The grids were negatively stained 
with 2 % uranyl acetate containing 0.7 M oxalate, pH 7.0, 
and imaged with a LEO EM912 Omega electron micro-
scope (Zeiss, Oberkochen). Digital micrographs were 
obtained with an on-axis 2048 CCD camera (Proscan, 
Scheuring).
Membrane preparation
Cells were washed twice with ice-cold PBS and collected 
into 200 µl homogenization buffer (20 mM Na-HEPES, 
1 mM EDTA, 0.32 M sucrose, pH 7.0). The cells were 
mechanically disrupted by 10× pipetting up and down 
through a yellow pipette tip and finally 10× through a 
27G needle. Cells were centrifuged at 4000 rpm for 5 min 
at 4 °C. The postnuclear supernatant was then ultracentri-
fuged with 196,000×g for 30 min at 4 °C. The pellet con-
taining membrane fraction and cytosol were resolved in 
sample buffer and subjected to SDS-PAGE and Western 
blotting.
Electrochemiluminescence assay for α‑Synuclein 
quantification
Quantification of α-Synuclein protein in cell lysates and 
extracellular vesicles derived from primary neuron cultures 
was performed as described [39] with slight modifications. 
Standard 96-well Multi-Array plates (Meso Scale Discov-
ery, Gaithersburg, USA) were coated with 3 µg/ml antibody 
MJF-1 clone 12.1 (kindly provided by Dr. Liyu Wu, Epi-
tomics, Burlingame, USA) in PBS. Plates were incubated 
overnight at 4 °C without shaking. All further steps were 
performed at room temperature. After washing, the plates 
three times with 150 µl PBS + 0.05 % Tween-20 block-
ing was performed with 150 µg 1 % BSA (Meso Scale Dis-
covery) for one hour under shaking at 300 rpm. A stand-
ard curve of recombinant α-Synuclein (kindly provided by 
Dr. Omar el-Agnaf, United Arab Emirates University, Al 
Ain, United Arab Emirates) was prepared in serial fourfold 
dilution starting at 25,000 pg/ml. After washing as above, 
standards and samples were applied at 25 µl per well in 
duplicate. Binding of analytes was allowed for 1 h under 
shaking at 700 rpm. Washing was done as above followed 
by addition of 25 µl Sulfo-TAG labelled anti-α-Synuclein 
clone 42/α-Synuclein (BD Transduction Laboratories, Hei-
delberg, Germany) at 1 µg/ml. Incubation was done for 
1 h under shaking at 700 rpm. After washing again 150 µl 
2 × Read Buffer T (Meso Scale Discovery™) was applied 
to each well and plates were measured in a Sector Imager 
6000 (Meso Scale Discovery™). Data analysis was per-
formed using MSD Discovery Workbench 3.0 Data Analy-
sis Toolbox.
Expression and purification of sumoylated α‑Synuclein
The expression and purification procedure of human 
sumoylated wild-type α-Synuclein was based on [38]. In 
brief, BL21 competent E. coli cells were co-transformed 
with the tricistronic plasmid pTE1E2S1, which codes for 
the expression of SUMO-1 and the E1 and E2 enzymes 
of the sumoylation pathway [70], and the pT7.7 encod-
ing for human wild-type α-Synuclein (courtesy of the 
P. Lansbury laboratory, Harvard Medical School, Cam-
bridge, MA). After enzymatic degradation of DNA, the 
bacterial extracts were heat precipitated at 95 °C for 
10 min and the supernatant subjected to column chroma-
tography (GE Healthcare Äkta system) with a sequence 
of 3 columns: Q Shepharose fast flow, HiLoad 26/600 
Superdex 200, and Mono Q 4.6/100 PE. Fractions of 
sumoylated α-Synuclein were combined and concen-
trated with an Amicon Ultracel Filter (10 kDa, Mil-
lipore), and purity assessed by polyacrylamide gel elec-
trophoresis (PAGE) and electrospray ionization mass 
spectroscopy (ESI–MS). The protein concentration was 
estimated using a molar extinction coefficient at 280 nm 
of 9080 M−1 cm−1.
Membrane binding of SUMO‑2: titration 
of SUMO‑2‑MFM with SUVs
The single Cys52 of SUMO-2 was labelled with the ESIPT 
probe MFM [60]. Unreacted Cys residues (<15 %) were 
blocked with a tenfold excess of N-ethylmaleimide and the 
labelled protein was purified through a PD10 column to sep-
arate it from unreacted probe. Single Unilamellar Vesicles 
(SUVs) were prepared by sonication as described previ-
ously [18] with a composition based on mixtures of POPC, 
POPS, and PIPs: (Avanti Polar Lipids, Alabaster, Alabama, 
USA). The relative molar compositions and approximate 
net relative molar charge densities were as follows (other 
ratios were also employed): POPC, 100, 0); POPC:POPS, 
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90:10; −0.1]; POPC:POPS:PI(3)P 85:10:5; −0.13]; 
POPC:POPS:PI(5)P 85:10:5; −0.14); POPC:POPS:PI(3,5)
P2 85:10:5; −0.2]; POPC:POPS:PI(4,5)P2 85:10:5, −0.2; 
and POPC:POPS:PI(3,4,5)P3, 85:10:5, −0.25. SUV stocks 
were quantified by determining inorganic phosphorus [24] 
and vesicles were used within 10 days of their preparation.
The titrations of the labelled protein with SUVs were 
performed with a new microplate assay (slopes, to be pub-
lished elsewhere; for more details contact author TMJ). 
This assay avoids the problems associated with conven-
tional fluorescence assays based on the addition of lipids 
to protein: signal contributions from lipid (emission and 
scattering), and photobleaching during the course of 
prolonged (and tedious) sequential additions. The strat-
egy of slopes exploits the maximal sensitivity of a titra-
tion performed with concentrations of the reagent in 
excess (the lipid) varied around the anticipated value(s) 
of the dissociation constant Kds. Lipid mixtures of vari-
ous concentrations bracketing the estimated Kd are pre-
pared with a small number of protein concentrations in 
the sub-µM range. Measurements of protein-derived sig-
nals at constant lipid concentration and varying protein 
yield straight linear relationships, the slopes of which 
depend on the fraction α of bound protein, given by the 
quantity α = [lipid]/(Kd + [lipid]). The slopes measured 
for a small number of protein concentrations are plot-
ted versus the lipid concentrations (usually 4, including 
0 concentration), from which Kd and the fluorescence 
enhancement factor are calculated from the relation: 
slope = f0[1 + (fe − 1)α, where f0 is the slope corre-
sponding to 0 lipid concentration and fe is the (enhanced) 
fluorescence of the bound protein relative to that of the 
free protein. Important advantages of this method are: (1) 
parallel readout in a microplate reader; (2) bottom readout 
with small optical path length and thus minimal scattering 
artefacts; (3) minimal reagent requirements; the protein 
concentration can be reduced to a minimum dictated only 
by the background signal and the probe sensitivity; (4) 
lack of photobleaching artefacts (single endpoint deter-
minations); and (5) accurate correction for potential sig-
nals introduced by components of the lipid mixtures. In 
the experiments reported in this study, the slopes method 
was enhanced by considering the apparent (measured) Kd 
value as the inverse of the sum of the reciprocal individual 
Kds for each lipid component weighted by the respective 
molar fractions. Thus, the entire series of lipid mixtures 
could be subjected to a global fitting procedure such as 
to derive the individual Kd values for POPC, POPS, and 
the PIs (those with affinities greater than that of POPS). 
The fe values were allowed to vary with lipid composi-
tion. We note that the derived Kd values implictly contain 
(as a multiplicative factor) the binding stoichiometry, i.e. 
the number of lipid molecules participating in the forma-
tion of the protein–lipid complex.
Solutions of SUMO-2-MFM (100, 200 and 300 nM) 
were prepared in 25 mM Na-HEPES, 100 mM KCl, pH 
7.26, with different (usually 7) SUV concentrations up to 
120 µM. Replicates (usually 2) of 100 µl were introduced 
into a 96-well quartz microplate (Hellma Analytics, Ger-
many) exhibiting very low background with excitation in the 
near-UV. After at least 10 min of incubation at room tem-
perature, the MFM T-band fluorescence excited at 340 nm 
was recorded at >510 nm in a Pherastar plate reader (BMG 
Labtech, Germany) operated in bottom readout, well scan 
mode with a matrix of 10 × 10, a scan diameter of 5 mm, 
and 20 flashes per well. Samples without protein and/or 
lipid were included to establish blank values and the lipid 
contributions to the measured signals. The data were ana-
lysed with procedures implemented in Mathematica (Wolf-
ram Research).
Expression of recombinant SUMO‑2 for NMR
SUMO-2 was cloned into pET11 and expressed as previ-
ously described [52]. For N15 labelling of SUMO-2 pro-
teins, bacterial cells were grown in one litre LB at 37 °C 
until the culture reached an optic density (OD600) of 0.6. 
Bacteria cultures were then centrifuged and resuspended 
in 500 ml standard Minimal M9 media containing 3 g 
glucose. Following 30 min of incubation, 1 g N15H4Cl 
was added to the medium, and cells were further grown 
for one hour at 37 °C, before induction with 1 mM IPTG. 
SUMO purification was performed as described, except 
that for gel-filtration analysis a buffer containing 20 mM 
NaH2PO4/Na2HPO4 pH 6.8, 100 mM KCl, 2 mM DTT 
was used.
NMR spectroscopy
To study the membrane binding of SUMO-2 by NMR 
200 µM 15N-labelled SUMO-2 in 20 mM NaH2PO4/
Na2HPO4, pH 6.8, 100 mM KCl, 1 mM DTT was 
titrated with increasing concentrations of 8, 16 and 
32 mM DHPC (1,2-dihexanoyl-sn-glycero-3-phos-
phocholine). 1H,15N-HSQC spectra were acquired at 
600 MHz and 22 °C on a triple resonance room temper-
ature probe with 16 transients, 2048 × 256 total points 
and sweep widths of 8418 × 2129 Hz (1H × 15N). Car-
rier frequencies were set to the water resonance for 
1H and to 117 ppm for 15N. Resonance assignments 
were taken from BMRB entry 11267. The normalized 
weighted average chemical shift difference for the 
amide proton and nitrogen was calculated according to 
�δ (HN) = [�δ2H + (0.2 × �δN)2]1/2.
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Results
Sumoylation is a sorting signal for release 
within extracellular vesicles
To elucidate if sumoylation may act as a sorting signal for 
ESCRT-dependent release within extracellular vesicles 
we generated a green fluorescent protein (GFP)-SUMO-2 
∆GG fusion construct, in which the deletion of the two 
C-terminal glycine residues prevents conjugation of SUMO 
to proteins. If not otherwise stated, conjugation-deficient 
mutants of SUMO-2 were for all further experiments. We 
prepared extracellular vesicles according to previously 
described protocols by subsequent centrifugation rounds 
including a final 100,000×g ultracentrifugation step 
from the medium of mouse neuroblastoma cells (N2a) as 
previously described [65]. N2a cells were transfected with 
either GFP-SUMO-2 or GFP as a negative control. Whereas 
GFP was excluded from the extracellular vesicle fraction, 
GFP-SUMO-2 was sorted into extracellular vesicles. The 
same was observed for GFP fused to a conjugation-defi-
cient-Ubiquitin construct (GFP-Ub) that we chose as a pos-
itive control based on the fact that mono-ubiquitination is a 
well-established sorting factor for release within extracellu-
lar vesicles (Fig. 1a). On a sucrose gradient, GFP-SUMO-2 
banded at a density of 1.11–1.16 g/ml similar to the extra-
cellular vesicle marker protein Alix (Fig. 1b). To rule out 
unspecific sorting of GFP-SUMO-2 into extracellular 
vesicles mediated by the GFP-fusion protein we prepared 
extracellular vesicles from N2a cells transiently transfected 
with either GFP-SUMO-2 or Myc-SUMO-2. Sorting of 
GFP- and Myc-tagged SUMO-2 into extracellular vesicles 
Fig. 1  SUMO-2 is released with extracellular vesicles. a N2a cells 
were transiently transfected with GFP or GFP either fused to a conju-
gation-deficient Ubiquitin mutant GFP-Ub or to the conjugation-defi-
cient SUMO-2 mutant GFP-SUMO-2. Lysates and EV fractions were 
subjected to Western blot analysis to detect GFP, GFP-Ub and GFP-
SUMO-2 in the cell lysate (lys) and the EV-fraction. The blot was 
also probed for Alix as a marker for EVs in the different preparations. 
Blots were scanned and analysed with Image J to determine the ratio 
of extracellular vesicle (EV) to cellular protein. Results are given as 
means + SEM, *p < 0.05, two-side t test (n = 8). b The 100,000g 
pellet from GFP-SUMO-2 transfected N2a cells was subjected to a 
discontinuous sucrose gradient. Fractions from 1.03 to 1.32 g/ml 
sucrose were blotted with antibodies against Alix and GFP. SUMO-2 
was recovered from 1.11 to 1.16 g/ml fractions, similar to Alix
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(Supplementary Fig. S1a) was indistinguishable, ruling out 
sorting mediated by GFP.
SUMO-1 and SUMO-2 share a 47 % homology [47]. In 
comparison of the GFP-fusion constructs of both SUMO 
isoforms, SUMO-1 was retrieved from the extracellular 
vesicle fraction, albeit to a lesser extent than SUMO-2 
(Supplementary Fig. S1b).
Having shown that SUMO protein is released within 
extracellular vesicles, we next asked whether it serves as a 
sorting signal. While extracellular vesicle targeting signals 
had not been described for cytosolic proteins before, mono-
ubiquitination of transmembrane proteins was reported 
to mediate their sorting to extracellular vesicles [54]. We 
therefore explored whether sumoylation might also target 
transmembrane proteins into extracellular vesicles. The 
amyloid precursor protein APP is a class 1 transmembrane 
protein involved in the pathogenesis of Alzheimer’s Dis-
ease. We transfected YFP-APP bearing the Swedish muta-
tion (APPsw K670N M671L) or the corresponding C-ter-
minal SUMO-2 fusion construct YFP-APPsw-SUMO-2 
into N2a cells. The fusion of conjugation-deficient SUMO2 
to YFP-APP (YFP-APP-SUMO-2) significantly increased 
release of APP with extracellular vesicles (Fig. 1c, Supple-
mentary Fig. S1c). Likewise, co-expression of APPsw with 
the conjugation-competent SUMO-2 wild type resulted 
in increased full-length APP release when compared to 
co-transfection of APPsw with the conjugation-deficient 
mutant SUMO-2 (Fig. 1d). Total amounts of EVs in both 
conditions were quantified by nanoparticle tracking analy-
sis and did not show significant differences between cells 
transfected with YFP-APPsw and YFP-APPsw-SUMO-2 
or cells co-tranfected with APPsw and SUMO-2 wild type 
or with the conjugation-deficient SUMO-2 ∆GG (Suppl. 
Table S1).
Extracellular vesicle release of SUMO‑2 is 
ESCRT‑dependent
The biogenesis of exosomes requires inward budding of 
the multivesicular endosome limiting membrane to gener-
ate intraluminal vesicles which are subsequently released 
as extracellular vesicles upon fusion of the multivesicu-
lar endosome with the plasma membrane. In contrast, 
microvesicles are formed by outward budding from the 
plasma membrane. Proteins can be targeted to intraluminal 
vesicle or microvesicle budding sites by ESCRT-depend-
ent or -independent mechanisms. To determine whether 
SUMO-2 is targeted to extracellular vesicles by the ESCRT 
machinery we used RNA interference (RNAi) against the 
ESCRT complex proteins Tsg101 and Alix or co-expressed 
the dominant negative (dn) mutant of VPS4 E233Q (See 
Supplementary Fig. S2 for quantification of RNAi). Deple-
tion of either ESCRT component resulted in a marked 
reduction of SUMO-2 release with extracellular vesicles 
(Fig. 2a). Co-expression of the dominant negative VPS4 
E233Q mutant together with the Moloney murine leukae-
mia virus Gag fused to GFP (MLV-Gag-GFP) or SUMO-2 
inhibited their extracellular vesicle release while secretion 
of the proteolipid protein (PLP) with extracellular vesicles 
was not affected, consistent with previous observations that 
PLP is sorted into extracellular vesicles in an ESCRT-inde-
pendent manner [68] (Fig. 2b).
Interaction of SUMO‑2 with the ESCRT complex does 
not depend on the SUMO SIM interaction motif
Having established an ESCRT-dependent mechanism for 
SUMO-2 release with extracellular vesicles, we next asked 
how SUMO-2 interacts with the ESCRT machinery. Non-
covalent protein binding of SUMO is often mediated by 
a conserved SUMO-interaction motif (SIM) in SUMO-
binding proteins, which is defined by a hydrophobic core 
often flanked by acidic residues [22]. The corresponding 
SIM interaction domain in SUMO-2 has been mapped 
to a groove between the α-helix and β-sheet of SUMO-
2, most prominently to amino acids Q 30 F 31 I 33 [29, 
66]. Mutation of these residues to alanine was shown to 
abolish SUMO-2 interaction with SIM domains [48, 75]. 
Tsg101 contains a putative SIM domain that might medi-
ate ESCRT-dependent sorting of SUMO-2 to extracellular 
vesicles. To explore whether extracellular vesicle sorting of 
SUMO-2 is mediated by a SIM-dependent direct or indi-
rect protein–protein interaction we introduced the QFI to 
AAA triple mutation into Myc-SUMO-2. Surprisingly, this 
mutation did not inhibit but instead increased the sorting of 
mutant SUMO-2 into extracellular vesicles (Fig. 3a). We 
therefore concluded that release of SUMO-2 with extracel-
lular vesicles was not likely to occur via a classical SIM-
mediated protein–SUMO interaction. Moreover, the disrup-
tion of the SIM interaction motif might rather increase the 
amount of unbound, cytosolic SUMO-2 that is available for 
allocation to the ESCRT formation sites.
SUMO‑2 interacts with phosphoinositols
Since the sorting of SUMO-2 into extracellular vesi-
cles does not appear to depend on SIM-mediated protein 
interactions, we asked whether SUMO-2 might interact 
with lipids for extracellular vesicle sorting and release. 
In different SUMO-2 interacting proteins, such as the E3 
SUMO ligase PIAS1, the tumour suppressor protein PML 
and the extracellular vesicle protein PMSCL1, phospho-
rylation of serine residues flanking the hydrophobic SIM 
core is a prerequisite for SUMO binding, indicating that 
SUMO-2 interacts with negatively charged domains [63]. 
Phosphorylated inositols have been demonstrated to serve 
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as regulators of cargo sorting to the ESCRT complex and 
into multivesicular endosomes. To gain insight into the pos-
sible direct interaction of SUMO-2 with lipids, the recog-
nition specificity of SUMO-2 for membranes of particular 
composition and charge was determined. We performed 
titration of the protein labelled with the polarity-sensitive 
excited-state intramolecular proton transfer (ESIPT) probe 
MFM [60] with small unilamellar vesicles according to a 
microplate assay devised for this purpose (see “Materials 
and methods”). Small unilamellar vesicles were prepared 
from mixtures of 1-palmitoyl,2-oleoyl-sn-glycero-3-phos-
phocholine (POPC) in various combinations with nega-
tively charged lipids: phosphatidylserine (POPS, 10 %) and 
low fraction (5 %) of the phosphoinositides PI(3)P, PI(5)
P, PI(3,5)P2, PI(4,5)P2 or PI(3,4,5)P3. The individual affin-
ity of each lipid for SUMO-2 in the mixture was calculated 
Fig. 2  Release of SUMO-2 
with extracellular vesicles is 
dependent on ESCRT. a N2a 
cells were treated with Tsg101 
or Alix siRNA as indicated 
36 h prior to transfection with 
GFP-SUMO-2. In the case of 
VPS4dn, Myc-SUMO-2 was co-
transfected with the dominant 
negative VPS4 mutant E233Q. 
The ratio of extracellular vesicle 
(EV) to cellular SUMO-2 (lys) 
was determined by Western 
blot analysis. Results are given 
as means + SEM, *p < 0.05, 
**p < 0.005, two-side t test 
(n = 12 for Alix, n = 6 for 
Tsg101, n = 4 for VPS4dn).  
b Interference with VPS4 func-
tion inhibits release of SUMO-2 
with extracellular vesicles. 
N2a cells were co-transfected 
with VPS4dn and either MLV-
Gag-GFP or GFP-SUMO-2 or 
PLP-Myc. Cells transfected 
with MLV-Gag-GFP, GFP-
SUMO-2 or PLP-Myc alone 
served as controls. Extracellular 
vesicles were prepared and cell 
lysates and vesicle pellets were 
subjected to Western blotting 
and probed with anti-GFP and 
anti-Myc antibodies. The ratio 
of protein in the extracellular 
vesicle fraction from cells 
co-transfected with VPS4dn 
to mock-transfected cells was 
quantified by Western blot 
analysis. Results are given as 
means + SEM, **p < 0.005, 
two-side t test (n = 5)
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from a global analysis of the combined data (Fig. 3b). We 
found that SUMO-2 binds to liposomes with the highest 
affinity for PI(3)P (Kd ~ 4.0 µM) followed by PI(3,4,5)P3 
and POPS (Kd 6–7 µM). Binding to uncharged POPC was 
much weaker, while PI(5P, PI(3,5)P2 and PI(4,5)P2 did not 
exhibit affinities discernably greater than that of POPS. 
Thus, negatively charged lipids appear to be required for 
finite binding and it is possible that only one or a few PI 
molecules, preferentially PI(3)P, suffice for significantly 
increasing affinity and, thereby, specificity of SUMO bind-
ing to lipid membranes. The comparison between PI(3)P 
(strong binding) and PI(5)P (weak binding) indicates that 
electrostatic interactions do not predominate, as suggested 
previously [25, 32]. However, the fluorescence enhance-
ment of the probe (fe) increased with negative charge 
density (Fig. 3b), indicating a strong influence of the lipid 
interaction site on the microenvironment of the bound 
protein.
Binding of SUMO-2 to either PI(3)P or PI(3,4,5)P3, 
which are known to recruit the ESCRT complex, might 
thus bring SUMO-2-modified proteins in close proximity 
to the ESCRT complex and explain SUMO-2-directed sort-
ing into extracellular vesicles. Whereas PI(3)P is predomi-
nantly localized to endosomal membranes, PI(3,4,5)P3 and 
phosphatidylserine are enriched in the inner leaflet of the 
plasma membrane [30]. To distinguish between multivesic-
ular body-mediated release and plasma membrane shedding 
of vesicles, we determined whether SUMO-2 was localized 
in intraluminal vesicles of multivesicular endosomes. To 
this end, we co-expressed SUMO-2 together with guano-
sine triphosphatase-deficient Rab5 (Rab5Q79L) which 
results in enlarged endosomes filled with intraluminal vesi-
cles [3, 68]. We found that SUMO-2 was completely absent 
from intraluminal vesicles in contrast to PLP, which was 
used as a positive control for multivesicular body-mediated 
sorting and release (Supplementary Fig. S3a) [68]. These 
findings suggest that SUMO-dependent budding into extra-
cellular vesicles might occur from the plasma membrane 
rather than from endosomal compartments. However, since 
small shedding microvesicles and multivesicular body-
derived exosomes cannot be distinguished by their physical 
or biochemical properties, further experiments are needed 
to ultimately distinguish between both pathways.
The membrane interaction motif of SUMO‑2 maps 
to the hydrophobic cleft and nearby loops
To identify the membrane interaction motif in SUMO-
2, we performed NMR spectroscopy on recombinant 
SUMO-2 upon 1,2-dihexanoyl-sn-glycero-3-phospho-
choline (DHPC) binding (Fig. 3c–e). Below the critical 
micellar concentration of DHPC only few chemical shift 
changes in SUMO-2 were observed (Fig. 3c). Primar-
ily residues in the hydrophobic cleft between the second 
β-strand and the α-helix (F31, K32, I33, L42 and Y46) 
showed a small chemical shift perturbation suggesting a 
hydrophobic interaction of the free phospholipids and the 
hydrophobic cleft. Above the critical micellar concentra-
tion, additional residues located to the loops at the N-ter-
minal side of SUMO-2 (Fig. 3d + e), in particular H16, 
H36 and D62, displayed strong changes in chemical shifts, 
indicating that the main interaction site of SUMO-2 with 
DHPC micelles is at the N-terminal end of the hydropho-
bic cleft and the nearby loops. This location partially over-
laps with the previously described protein interaction site 
of SUMO-2 at Q30 F31 I33. Of note, the loop of D62, and 
Fig. 3  a Mutation of the SIM interacting motif in GFP-SUMO-2 
(Q 30 F 31 I 33 to A30 A31 A 33) does not inhibit EMV SUMO-2 
release. N2a cells were transfected with either SUMO-2 or the 
SUMO-2 triple A mutant (∆SIM). EMV release was quantified by 
Western blot analysis. Results are given as means + SEM, *p < 0.05, 
two-side t test (n = 10). b Titration of SUMO-2-MFM with SUVs 
containing POPC, POPC/POPS, or POPC/POPS supplemented with 
either PI(3)P, PI(5)P, PI(3,5)P2, PI(4,5)P2 or PI(3,4,5)P3. The affini-
ties of each lipid contributing to the apparent affinity of the protein 
for the liposome were calculated as described in Methods. Kds are 
given ±standard measurement errors. The values corresponding 
to PI(5)P, PI(3,5)P2 and PI(4,5)P2 were too high to be determined 
(affinity less than that of the POPS co-lipid, i.e. >7 µM). N = 19 titra-
tions; statistically significant differences were obtained for POPC 
versus POPS (p < 0.001), and POPS versus PI(3)P (p = 0.01). No 
significant difference was found for PI(3,4,5)P3 versus PS. The fluo-
rescence enhancement factors (fe) are indicated with their respec-
tive standard measurement errors. See “Materials and methods” for 
further details. Membrane binding of SUMO-2 analysed by NMR 
spectroscopy. c Mean weighted 1H-15N chemical shifts of Sumo-2 
at DHPC concentrations of 8 mM (white bars), 16 mM (grey bars) 
and 32 mM (black bars). Below the critical micellar concentra-
tion (CMC) of DHPC of 16 mM only few chemical shift changes 
in SUMO-2 were observed (d + e) The chemical shift perturbation 
at 32 mM DHPC is plotted onto the SUMO-2 NMR structure (pdb-
code: 2AWT). Residues in red display a perturbation greater than 
0.03 ppm and residues in orange between 0.02 and 0.03 ppm. The 
structure in panel d is rotated by 90º relative to panel (e). f Mutations 
of the SUMO-2 cleft and loop domains decrease membrane binding 
N2a cells transfected with Myc-SUMO-2, Myc-SUMO-2 cleft mutant 
or Myc-SUMO-2 cleft + loop mutant. The postnuclear supernatant 
of the mechanically disrupted cells was centrifuged at 196,000×g 
for 30 min to separate the membrane-containing pellet and the cyto-
solic supernatant. Membrane pellets and a proportion of the total 
cell lysate and the cytosol-containing supernatant were subjected to 
Western blot analysis with anti-Myc antibody to quantify the ratio of 
membrane associated SUMO-2. Results are given as means + SEM, 
***p < 0.0005, two-side t test (n = 8). g Mutations of the SUMO-2 
cleft and loop domains decrease extracellular vesicle release. N2a 
cells were transfected with Myc-SUMO-2, Myc-SUMO-2 cleft 
mutant or Myc-SUMO-2 cleft + loop mutant. Lysates and EV frac-
tions were subjected to Western blot analysis to detect the different 
SUMO constructs in the cell lysate (lys) and the EV-fraction. The blot 
was also probed for Alix as a marker for EVs in the different prepa-
rations. Blots were scanned and analysed with Image J to determine 
the ratio of extracellular vesicle (EV) to cellular protein. Results 
are given as means + SEM, *p < 0.05, **p < 0.005, two-side t test 
(n = 9)
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the corresponding loop in SUMO-1 were previously shown 
to interact with SUMO-conjugating enzyme Ubc9 [11, 15, 
35] and the dipeptidyl peptidase DPP9 [53]. To prove that 
residues in the hydrophobic cleft and in the N-terminal 
loop indeed mediate membrane binding of SUMO-2, we 
introduced a series of mutations at residues Q30, F31, K32, 
I33, L42, Y46 within the hydrophobic cleft (SUMO-2 cleft) 
and additionally at H16, H36 and D62 in the N-terminal 
loop (SUMO-2 cleft + loop). Indeed, membrane bind-
ing of these mutants was decreased compared to SUMO-2 
(Fig. 3f). Supporting our hypothesis that SUMO-2 interacts 
with lipid membranes for sorting into extracellular vesicles 
we found that the release of both mutants within extracel-
lular vesicles was reduced compared to SUMO-2 (Fig. 3g, 
Supplementary Fig. S3b).
Having established SUMO modification as a novel sort-
ing determinant for proteins into extracellular vesicles, we 
next investigated its relevance for the targeting of other pro-
teins into extracellular vesicles. In neurodegenerative dis-
eases, extracellular vesicles have been proposed as a poten-
tial carrier to disseminate misfolded proteins and thereby 
contribute to spreading of disease pathology [1]. A proto-
typic example is α-Synuclein, which is a major component 
of intracellular Lewy bodies (LBs) that neuropathologically 
define Parkinson’s disease (PD) and dementia with Lewy 
bodies (DLB) [62]. We have recently described two major 
sumoylation sites at K96 and K102 in α-Synuclein [38]. 
Therefore, we wondered if sumoylation of these sites might 
modulate extracellular release of α-Synuclein.
α‑Synuclein is localized in extracellular vesicles in vivo
It is not known whether α-Synuclein exists in extracellular 
vesicles in vivo or how it might be sorted to the extracellular 
vesicle pathway. To address these issues we first analysed 
whether α-Synuclein is present in extracellular vesicles 
in the human central nervous system (CNS). We prepared 
extracellular vesicles from lumbar cerebrospinal fluid by 
several centrifugation rounds including a final 100,000×g 
ultracentrifugation step (Supplementary Fig. S4a). Elec-
tron microscopy of the resulting pellet revealed 50–100 nm 
structures with morphological features of extracellular vesi-
cles (Supplementary Fig. S4b). The pellet was enriched in 
the extracellular vesicle proteins Flotillin-2 and CD63 in 
addition to the Glutamate Receptors- 1, -2 and -3. The latter 
finding indicates that extracellular vesicles in the cerebrospi-
nal fluid are at least partially derived from the CNS (Suppl. 
Fig. S4c). Microsomal proteins such as the endoplasmatic 
reticulum (ER) marker Calnexin and the trans-Golgi net-
work (TGN) protein γ-Adaptin were absent, thus exclud-
ing organelle contamination of the extracellular vesicle 
preparation (data not shown). Of note, sumoylated proteins 
were detected in CSF-derived extracellular vesicles with 
a moderate enrichment of several proteins in this fraction 
(Supplementary Fig. S4d). On a sucrose gradient, Flotillin-2 
was enriched in fractions with a density of 1.16–1.24 g/ml 
which is consistent with previously published results for 
Flotillin-positive extracellular vesicles [3] (Supplementary 
Fig. S4e). Western blot analysis of total cerebrospinal fluid 
and the corresponding 100,000×g pellet revealed the pres-
ence of α-Synuclein in the extracellular vesicle containing 
pellet (Supplementary Fig. S4f). Sucrose gradient centrifu-
gation of CSF-derived extracellular vesicles followed by 
electrochemiluminescence assay detection of α-Synuclein 
revealed a flotation behaviour similar to the extracellular 
vesicle marker protein Flotillin-2 (Supplementary Fig. S4g). 
These findings establish that extracellular vesicle-associated 
α-Synuclein indeed exists in the CNS in vivo and might 
therefore play a key role in the pathology of the disease.
α‑Synuclein is predominantly localized in the lumen 
of extracellular vesicles
In line with previous results from studies of immortalized 
cell lines [16] we found by sucrose gradient and Western 
blot analysis that α-Synuclein is released with extracellu-
lar vesicles (electron micrograph, Supplementary Fig. S5a) 
from transiently transfected N2a cells and the oligodendro-
glial cell line Oli-neu (Supplementary Fig. S5b + c and 
data not shown). Overexpression of exogenous α-Synuclein 
might artificially lead to its extracellular vesicle-dependent 
release. However, the fact that α-Synuclein is present in the 
extracellular vesicle fraction in human cerebrospinal fluid 
argues in favour of extracellular vesicle-associated release 
Fig. 4  Sumoylation regulates release of α-Synuclein with extracel-
lular vesicles. a Release of 2KR and 2AA mutants into extracellular 
vesicles from N2a cells (n = 6). b Human embryonic kidney (HEK) 
cells were treated with Ubc9 siRNA or mock treated 36 h prior to 
transfection with α-Synuclein wild type. The ratio of extracellular 
vesicle (EV) to cellular α-Synuclein (lys) was determined by Western 
blot analysis. Alix was blotted as a positive control for EV prepara-
tions. Results are given as means + SEM, **p < 0.005, two-side t 
test (n = 6). c α-Synuclein wild type and α-Synuclein-SUMO-2 were 
transiently transfected and extracellular vesicle release measured by 
Western blot (n = 8). d Co-transfection of α-Synuclein wild type 
with either SUMO-2 wild type or the conjugation-deficient SUMO-2 
∆GG mutant. Extracellular vesicle release of α-Synuclein was deter-
mined by Western blot analysis (n = 10). e α-Synuclein-SUMO-2 
was co-transfected with a VPS4 dominant negative mutant E233Q 
and extracellular vesicle release of Myc-α-Synuclein-SUMO-2 was 
quantified. (n = 12). All results are given as mean + SEM; *p < 0.05; 
**p < 0.005, ***p < 0.0005. Student’s t test. The exosome blot mem-
branes were additionally probed with an antibody against Flotillin-2 
or Alix as an exosomal marker protein (upper panel). Total extracel-
lular vesicle numbers were quantified by nanoparticle tracking anal-
ysis of the culture medium and showed no difference between wild 
type and mutant transfected cells (a, c, d) and a significant reduction 
of extracellular vesicle release in the case of VPS4dn co-transfection 
(e) (Table S1)
▸
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even at physiological expression levels. In addition, we 
found by electrochemiluminescence assay analysis that 
endogenous α-Synuclein is released within extracellular 
vesicles at levels comparable to the extracellular vesicle 
marker protein Alix (Supplementary Fig. S5d).
Trypsin digestion of extracellular vesicle preparations 
revealed that α-Synuclein resides within the vesicles rather 
than being attached to the external membrane (Supple-
mentary Fig. S5e + f). Trypsin digestion conditions were 
selected to ensure that Flotillin-2, a bona fide intraluminal 
extracellular vesicle protein, was protected from proteoly-
sis. The silver gel shows degradation bands in the trypsin-
treated 100,000×g pellet compared to the non-trypsinized 
control. Western blot analysis demonstrated that the content 
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of Flotillin-2 and α-Synuclein in the extracellular vesi-
cle pellet was unaltered by trypsin treatment, indicating 
that, as in the case of Flotillin, α-Synuclein is localized in 
the vesicle lumen (Supplementary Fig. S5e). In contrast, 
α-Synuclein was degraded to a similar extent as the intra-
luminal protein Alix when vesicles were trypsinized in the 
presence of 1 % Triton (Supplementary Fig. S5f).
Sumoylation regulates extracellular vesicle release 
of α‑Synuclein
The mechanism responsible for sorting of the cytosolic 
protein α-Synuclein into the extracellular vesicle pathway 
is unknown. To test whether sumoylation might regulate 
the release of α-Synuclein with extracellular vesicles, we 
transiently transfected N2a cells with Myc-α-Synuclein 
mutants which interfere with the protein’s sumoylation. 
Myc-α-Synuclein K96R K102R bears a double mutation 
(2KR) at two sumoylation sites which account for more 
than 50 % of SUMO conjugation. The D98A E104A dou-
ble mutation (2AA) disrupts the consensus motif for recog-
nition of adjacent SUMO receptor lysines [38]. As we have 
shown previously, neither the 2KR nor the 2AA mutation 
impairs ubiquitination of α-Synuclein while both reduce 
sumoylation to a similar extent [38].
Both sumoylation-deficient mutants were significantly 
reduced in the extracellular vesicle fraction of N2a and 
adeno-associated virus (AAV) infected primary corti-
cal neurons, supporting our hypothesis that sumoylation 
increases release within extracellular vesicles (Fig. 4a, 
Supplementary Fig. S6a). Consistent with these results, the 
silencing of the E2 conjugating enzyme Ubc9 by siRNA 
(Supplementary Fig. S6b) to prevent sumoylation, resulted 
in a strong decrease of α-Synuclein release within extracel-
lular vesicles (Fig. 4b) [7].
Next, we generated a Myc-a-Synuclein-SUMO-2 fusion 
protein mimicking constitutive SUMO modification and 
harbouring the ∆GG mutation to prevent SUMO conjuga-
tion to other proteins.
In line with the notion that SUMO conjugation enhances 
α-Synuclein release within extracellular vesicles, Myc-α-
Synuclein-SUMO-2 was highly enriched in the extracellu-
lar vesicle preparation (Fig. 4c, Supplementary Fig. S6c). 
In a similar fashion, enhancing SUMO modification of 
Myc-α-Synuclein wild type by co-expression with Myc-
SUMO-2 wild type significantly increased the fraction 
of α-Synuclein in extracellular vesicles compared to co-
expression of the conjugation-deficient SUMO mutant 
Myc-SUMO-2 ∆GG (Fig. 4d). No difference was observed 
for the extracellular vesicle marker proteins Flotillin-2 and 
Alix or the total extracellular particle numbers, indicat-
ing that overexpression of SUMO-2 does not increase the 
production of extracellular vesicles itself (Supplementary 
Fig. S7; Table S1).
We could not detect a marked enrichment of the 
sumoylated α-Synuclein band in extracellular vesicles on 
Western blots due to an isopeptidase activity in extracellular 
vesicles that resulted in rapid de-conjugation (Supplemen-
tary Fig. S8a). Therefore, we used a luciferase-based protein 
fragment complementation assay [12] which allowed direct 
measurement of α-Synuclein-SUMO-2 interaction. As dem-
onstrated in Supplementary Fig. S8b the strong physical 
interaction between α-Synuclein and SUMO-2 suggests that 
sumoylated α-Synuclein is enriched in extracellular vesicles 
compared to total cell lysates (Supplementary Fig. S8b).
The release of sumoylated α-Synuclein within extracel-
lular vesicles was ESCRT-dependent since co-expression 
of VPS4 dn strongly reduced the release of the constitu-
tively “sumoylated” Myc-α-Synuclein-SUMO-2 fusion 
construct within extracellular vesicles (Fig. 4e). Similar to 
SUMO-2 and in contrast to PLP, α-Synuclein was absent 
from intraluminal vesicles in Rab5Q79L-transfected cells 
characterized by enlarged endosomes filled with intralu-
minal vesicles (Supplementary Fig. S9). This data indicate 
Fig. 5  Membrane binding regulates release of α-Synuclein within 
extracellular vesicles. a N2a cells were transfected with wild-type 
or N-terminally truncated α-Synuclein (∆N). Cells were scraped 
and disrupted mechanically. The postnuclear supernatant was ultra-
centrifuged at 196,000×g for 30 min to separate the membrane-
containing pellet and the cytosolic supernatant. Complete pellets 
and a proportion of the total cell lysate and the cytosol-containing 
supernatant were subjected to Western blot analysis with anti-α-
Synuclein antibody to quantify the ratio of membrane associated 
α-Synuclein (n = 8). b Extracellular vesicles were prepared from 
the medium of N2a cells transfected with α-Synuclein wild type or 
∆N and the ratio of extracellular vesicle to cell lysate protein was 
quantified upon Western blotting (n = 8). c Membrane pellets were 
prepared from cells after transfection with either α-Synuclein wild 
type (n = 12), the sumoylation-deficient mutant 2KR (n = 12) or 
the sumoylation consensus sequence mutant 2AA (n = 6). (d) Simi-
lar experiment as in (c) with transiently transfected α-Synuclein wild 
type and α-Synuclein-SUMO-2 (n = 6). e 2D fluorescence inten-
sity histograms of SIFT recordings show binding of recombinant 
α-Synuclein (red) and sumoylated α-Synuclein (red) to DPPC lipid 
vesicles (green) (see also schematic drawing: α-Synuclein red bar; 
sumoylated α-Synuclein red bar with dot; DPPC lipid vesicles green 
circle). f In contrast to sumoylated α-Synuclein, non-sumoylated 
α-Synuclein is released from the lipid vesicles following addition of 
an ~1000-fold excess of unlabelled α-Synuclein (schematic draw-
ing in e white bar). Left dose response curve for the effect of non-
sumoylated α-Synuclein on the vesicle binding of sumoylated and 
non-sumoylated α-Synuclein (mean values + SEM normalized to 
reference (addition of buffer) of duplicate measurements of three 
parallel samples). Right time course of release of α-Synuclein and 
sumoylated α-Synuclein from lipid vesicles after addition of 7 µM 
unlabelled α-Synuclein in a representative experiment. g Summary 
of α-Synuclein membrane binding and release with extracellular vesi-
cles. All results are given as mean + SEM; *p < 0.05; **p < 0.005, 
***p < 0.0005. Student’s t test
▸
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that α-Synuclein-positive extracellular vesicles might bud 
directly from the plasma membrane, although release via 
the multivesicular body pathway cannot be excluded.
Release of α‑Synuclein within extracellular vesicles is 
regulated by membrane binding
As demonstrated above, SUMO–ESCRT interaction 
involves the binding of SUMO to lipids. We therefore 
assumed that sumoylation regulates α-Synuclein release by 
modulating α-Synuclein binding to the formation sites of 
extracellular vesicles at the plasma membrane. Membrane 
binding of α-Synuclein was determined by mechanical 
disruption of the cells followed by 196,000×g ultracen-
trifugation of the postnuclear supernatant. The membrane-
containing pellet and the membrane-free, cytosolic super-
natant fraction were subjected to Western blot analysis. 
Membrane association of α-Synuclein has been described 
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as a two-step process with binding of amino acids 3–25 fol-
lowed by a conformational shift of residues 26–100 into a 
α-helical structure which cooperatively binds to the mem-
brane [4, 8].
Indeed, membrane binding of an N-terminal deletion 
construct of α-Synuclein lacking amino acids 2-19 (Myc-
α-Synuclein ∆N) is significantly reduced [4, 34] (Fig. 5a, 
Supplementary Fig. S10a) and α-Synuclein ∆N was largely 
excluded from extracellular vesicles in contrast to wild-
type α-Synuclein in transiently transfected N2a and Oli-
neu cells (Fig. 5b and data not shown).
In line with our results above, we found that both 
SUMO-deficient α-Synuclein mutations, Myc-α-Synuclein 
2KR and Myc-α-Synuclein 2AA significantly attenuated 
membrane binding of α-Synuclein compared to Myc-α-
Synuclein wild type (Fig. 5c, Supplementary Fig. S10b).
In contrast, the Myc-α-Synuclein-SUMO-2 fusion 
construct was markedly enriched in the membrane pellet 
compared to Myc-α-Synuclein (Fig. 5d). Similar results 
were obtained in a fluorescence correlation spectroscopy 
(FCS) SIFTs assay [31], in which sumoylated recombinant 
α-Synuclein competed with non-sumoylated α-Synuclein 
for binding to dipalmitoyl-sn-glycero-3-phospho-choline 
(DPPC) vesicles (Fig. 5e + f). In contrast to sumoylated 
α-Synuclein, non-sumoylated α-Synuclein could be 
released from the lipid vesicles following the addition of 
a ~1000-fold excess of unlabelled α-Synuclein (Fig. 5f). 
Taken together, sumoylation of α-Synuclein promotes its 
binding to membranes, thereby increasing its release within 
extracellular vesicles (Fig. 5g).
Discussion
Here, we show that sumoylation can serve as a sorting 
determinant for the release of proteins within extracellular 
vesicles. Our findings on SUMO-dependent sorting of GFP, 
APP and α-Synuclein into extracellular vesicles represent 
examples of this pathway.
After sucrose gradient flotation SUMO-2, APP and 
α-Synuclein were recovered at a density indicative of extra-
cellular vesicles. For quantitative comparison of extracellular 
vesicle release, we preferred an ultracentrifugation protocol 
to sucrose gradient preparations. Therefore, one limitation 
of our study is a possible contamination of the ultracen-
trifugation pellet with other vesicles and protein aggregates 
[46, 67]. This especially concerns α-Synuclein which could 
be aggregated in the cell culture medium and co-sediment 
with extracellular vesicles during ultracentrifugation. How-
ever, the results from our trypsin digestion assay indicate 
that the vast majority of α-Synuclein recovered from the 
ultracentrifugation pellet is encapsulated in vesicles, rather 
than attached to the vesicular surface. Conflicting results had 
previously been reported for the localization of extracellu-
lar vesicle-associated α-Synuclein [12]. There, a substantial 
proportion of α-Synuclein in the extracellular vesicle prepa-
ration was accessible to trypsin digestion, indicating that 
α-Synuclein may be localized at the outer vesicle membrane. 
However, extracellular vesicles in that study were frozen 
after preparation and prior to trypsin digestion (Danzer, per-
sonal communication). In our assay, all vesicle preparations 
were digested immediately after preparation since freezing 
likely interferes with membrane integrity, making intrave-
sicular protein accessible to trypsin. Under these experimen-
tal conditions, α-Synuclein was not degraded by trypsin and 
hence most likely localized within the vesicles.
Our results suggest that SUMO-2-dependent sorting to 
extracellular vesicles requires the ESCRT complex and is 
mediated by SUMO-2 interaction with phosphoinositols. 
Highest lipid-binding affinities were detected for SUMO-2 
interaction with PI3P and PI(3,4,5)P3, indicating that both 
binding partners could serve as potential pathways to the 
ESCRT complex. Extracellular vesicles can either be derived 
from late endosomes/multivesicular bodies or shed from the 
plasma membrane. PI(3,4,5)P3 is predominantly localized at 
the plasma membrane in contrast to PI3P which is enriched 
at the endosomal membrane. Both lipids can interact with 
the ESCRT machinery. ESCRT-0 can be recruited to sites of 
intraluminal vesicle formation by binding of the Hrs FYVE 
domains to PI(3)P. Fusion of the cytosolic protein TyA with 
the PI(3,4,5)P3-binding domain of AKT protein kinase effi-
ciently targets the protein to extracellular vesicle budding 
sites at the plasma membrane [58]. Based alone on the lipid-
binding affinities of SUMO-2 for PI3P and PI(3,4,5)P3, it is 
not possible to distinguish between the multivesicular body 
and the plasma membrane shedding pathway for SUMO-2 
release. We therefore overexpressed Rab5Q79L which 
blocks endosomal maturation and leads to the accumula-
tion of intraluminal vesicles (ILVs) in enlarged endosomes. 
Using this method, we could neither detect SUMO-2 nor 
α-Synuclein in Rab5Q79L-induced endosomal ILVs. This 
suggests that SUMO-2 might bind to the plasma membrane 
for subsequent shedding into vesicles rather than being 
sorted into multivesicular endosome-derived ILVs. A spatial 
selectivity of SUMO-2 to PI(3,4,5)P3 binding at the plasma 
membrane may be caused by differences in the cholesterol to 
phospholipid ratio which is higher in the plasma membrane 
compared to endosomal membranes [72]. Interestingly, the 
presence of cholesterol enhances the binding of the tumour 
suppressor phosphatase and tensin homologue PTEN to 
a variety of different phosphoinositides [33], presumably 
by cholesterol-induced segregation of phosphoinositides, 
thereby reducing their electrostatic repulsion [33]. Sumoyla-
tion was previously described to mediate PTEN relocaliza-
tion to the plasma membrane where it dephosphorylates 
PI(3,4,5)P3 [25, 32]. Of note, the release of PTEN within 
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extracellular vesicles was reported recently [21]. Based on 
the rab5Q79L overexpression experiment alone, it cannot 
be excluded that small amounts of SUMO-2 bud into multi-
vesicular endosomes which are not detected by microscopy. 
In addition, rab5Q79L overexpression may not inhibit the 
maturation of all endosomes to multivesicular endosomes. 
Although vesicles within rab5Q79L endosomes are posi-
tive for a set of ILV marker proteins and their morphology 
resembles that of ILVs within multivesicular bodies derived 
from late endosomes, we cannot rule out that there are slight 
differences between those vesicles trapped within rab5Q79L 
endosomes and those present in multivesicular endosomes. 
We can therefore not exclude that SUMO-2 is released by 
the multivesicular endosome/exosome pathway. Especially, 
since both types of extracellular vesicles cannot be sepa-
rated by ultracentrifugation and sucrose gradient centrifuga-
tion protocols or based on specific marker proteins, further 
experimentation is clearly required to ultimately distinguish 
between both pathways.
Taken together, our data on GFP-SUMO-2, α-Synuclein 
and APP strongly support the concept of a SUMO modi-
fication as a novel sorting signal to extracellular vesicles 
which is ESCRT-dependent. Targeting of proteins to the 
vesicle formation site may be achieved by interaction with 
phosphorylated inositols, possibly at the plasma membrane.
A prion-like transmission of α-Synuclein aggregates includ-
ing intercellular spreading and templating of further pathological 
aggregate formation in recipient cells had been proposed recently 
[6, 57]. This hypothesis is mainly based on the temporo-spatial 
spreading of α-Synuclein pathology in Parkinson’s disease [10] 
and further supported by the observation of α-Synuclein aggre-
gates in embryonic midbrain neurons which had been trans-
planted into Parkinson’s disease patients’ brains [36, 43]. Further 
evidence stemmed from murine in vivo and in vitro models, 
where the uptake of recombinant α-Synuclein fibrils in neurons 
was detected, followed by the induction of α-Synuclein aggre-
gation [12, 16, 44, 45, 49, 50, 74]. Several reports have indeed 
shown a-Synuclein associated with extracellular vesicles [17, 69] 
and recently we provided evidence for the exosome-mediated 
propagation of oligomeric α-Synuclein in vitro [12].
However, in the absence of a conventional secretion sig-
nal in α-Synuclein, the mechanisms which lead to its extra-
cellular release remained elusive so far. Our results show 
for the first time that α-Synuclein is present in extracellular 
vesicles in the CNS in vivo and shed light on the molecu-
lar mechanisms which direct α-Synuclein into vesicles. Our 
findings are thus of highest relevance for the understand-
ing of Parkinson’s disease pathogenesis and progression at 
the molecular level. Therefore, our results may have impor-
tant consequences for the development of novel therapeu-
tic strategies to treat Parkinson’s disease. In summary, our 
findings also assign SUMO modification of proteins a pre-
viously unknown cell biological function.
Acknowledgments We are grateful to Frauke Melchior, University 
Heidelberg, Germany, for helpful discussions. A. S., J. H. W., M. K., 
M. Z., K. S and K. E. were supported by Grants from the German 
Research foundation Cluster of Excellence “Nanoscale Microscopy 
and Molecular Physiology of the Brain” (CNMPB) and the Center for 
Molecular Physiology of the Brain (CMPB). A. S. received funding by 
the German Research Foundation (Deutsche Forschungsgemeinschaft) 
Grants SCHN1265 2-1 and 1-1 and was funded under the ERA-NET 
scheme of the Seventh Framework Programme of the European Com-
mission (EuroNanoMed II,GlioEx). A. S., B. M. and N. K. were 
funded by the Michael J. Fox Foundation of Parkinson’s Research. T. 
J. was supported by the (German Federal Ministry of Education and 
Research (BMBF) Grant #315050 and the Max Planck Society. J. G. 
received support from the China Scholarship Council (CSC).
Conflict of interest The authors declare that they have no conflict 
of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Aguzzi A, Rajendran L (2009) The transcellular spread of cyto-
solic amyloids, prions, and prionoids. Neuron 64:783–790. 
doi:10.1016/j.neuron.2009.12.016 pii: S0896-6273(09)01006-X
 2. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, 
Wood MJ, Cooper JM (2011) Lysosomal dysfunction increases 
exosome-mediated alpha-synuclein release and transmission. 
Neurobiol Dis 42:360–367. doi:10.1016/j.nbd.2011.01.029
 3. Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geer-
aerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E et al 
(2012) Syndecan-syntenin-ALIX regulates the biogenesis of 
exosomes. Nat Cell Biol 14:677–685. doi:10.1038/ncb2502
 4. Bartels T, Ahlstrom LS, Leftin A, Kamp F, Haass C, Brown MF, 
Beyer K (2010) The N-terminus of the intrinsically disordered 
protein alpha-synuclein triggers membrane binding and helix 
folding. Biophys J 99:2116–2124. doi:10.1016/j.bpj.2010.06.035
 5. Becker J, Barysch SV, Karaca S, Dittner C, Hsiao HH, Ber-
riel Diaz M, Herzig S, Urlaub H, Melchior F (2013) Detecting 
endogenous SUMO targets in mammalian cells and tissues. Nat 
Struct Mol Biol 20:525–531. doi:10.1038/nsmb.2526
 6. Bellingham SA, Guo BB, Coleman BM, Hill AF (2012) 
Exosomes: vehicles for the transfer of toxic proteins associ-
ated with neurodegenerative diseases? Front Physiol 3:124. 
doi:10.3389/fphys.2012.00124
 7. Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD (2002) 
Structural basis for E2-mediated SUMO conjugation revealed 
by a complex between ubiquitin-conjugating enzyme Ubc9 and 
RanGAP1. Cell 108:345–356
 8. Bodner CR, Maltsev AS, Dobson CM, Bax A (2010) Differen-
tial phospholipid binding of alpha-synuclein variants implicated 
in Parkinson’s disease revealed by solution NMR spectroscopy. 
Biochemistry 49:862–871. doi:10.1021/bi901723p
 9. Braak H, Del Tredici K, Rub U, de Vos RA, JansenSteur EN, Braak E 
(2003) Staging of brain pathology related to sporadic Parkinson’s 
disease. Neurobiol Aging 24:197–211 pii: S0197458002000659
 10. Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Par-
kinson’s disease: possible routes by which vulnerable neuronal 
types may be subject to neuroinvasion by an unknown pathogen. 
J Neural Transm 110:517–536. doi:10.1007/s00702-002-0808-2
712 Acta Neuropathol (2015) 129:695–713
1 3
 11. Capili AD, Lima CD (2007) Structure and analysis of a complex 
between SUMO and Ubc9 illustrates features of a conserved 
E2-Ubl interaction. J Mol Biol 369:608–618. doi:10.1016/j.
jmb.2007.04.006
 12. Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow 
AR, Zhu L, Vanderburg CR, McLean PJ (2012) Exosomal cell-
to-cell transmission of alpha synuclein oligomers. Mol Neurode-
gener 7:42. doi:10.1186/1750-1326-7-42
 13. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe 
C, Hyman BT, McLean PJ (2011) Heat-shock protein 70 modu-
lates toxic extracellular alpha-synuclein oligomers and rescues 
trans-synaptic toxicity. FASEB J 25:326–336. doi:10.1096/
fj.10-164624
 14. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, 
Spencer B, Masliah E, Lee SJ (2009) Inclusion formation and 
neuronal cell death through neuron-to-neuron transmission of 
alpha-synuclein. Proc Natl Acad Sci USA 106:13010–13015. 
doi:10.1073/pnas.0903691106 (0903691106 [pii])
 15. Duda DM, van Waardenburg RC, Borg LA, McGarity S, Nourse 
A, Waddell MB, Bjornsti MA, Schulman BA (2007) Structure 
of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: con-
servation of a non-covalent ubiquitin-like protein-E2 complex as 
a platform for selective interactions within a SUMO pathway. J 
Mol Biol 369:619–630. doi:10.1016/j.jmb.2007.04.007
 16. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, 
Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K (2010) Cell-pro-
duced alpha-synuclein is secreted in a calcium-dependent manner 
by exosomes and impacts neuronal survival. J Neurosci 30:6838–
6851. doi:10.1523/JNEUROSCI.5699-09.2010 (30/20/6838 [pii])
 17. Emmanouilidou E, Stefanis L, Vekrellis K (2010) Cell-produced 
alpha-synuclein oligomers are targeted to, and impair, the 26S 
proteasome. Neurobiol Aging 31:953–968. doi:10.1016/j.
neurobiolaging.2008.07.008
 18. Falomir-Lockhart LJ, Franchini GR, Guerbi MX, Storch J, Cor-
sico B (2011) Interaction of enterocyte FABPs with phospholipid 
membranes: clues for specific physiological roles. Biochim Bio-
phys Acta 1811:452–459. doi:10.1016/j.bbalip.2011.04.005
 19. Fitzner D, Schneider A, Kippert A, Mobius W, Willig KI, Hell 
SW, Bunt G, Gaus K, Simons M (2006) Myelin basic protein-
dependent plasma membrane reorganization in the formation of 
myelin. EMBO J 25:5037–5048. doi:10.1038/sj.emboj.7601376 
(7601376 [pii])
 20. Frohlich D, Kuo WP, Fruhbeis C, Sun JJ, Zehendner CM, Luh-
mann HJ, Pinto S, Toedling J, Trotter J, Kramer-Albers EM 
(2014) Multifaceted effects of oligodendroglial exosomes on 
neurons: impact on neuronal firing rate, signal transduction and 
gene regulation. Philos Trans R Soc Lond Ser B Biol Sci 369. 
doi:10.1098/rstb.2013.0510
 21. Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, 
Qureshi T, Al-Nedawi K (2013) Regulation of the tumor suppres-
sor PTEN through exosomes: a diagnostic potential for prostate 
cancer. PLoS One 8:e70047. doi:10.1371/journal.pone.0070047
 22. Geiss-Friedlander R, Melchior F (2007) Concepts in sumoylation: 
a decade on. Nat Rev Mol Cell Biol 8:947–956. doi:10.1038/
nrm2293
 23. Giese A, Bader B, Bieschke J, Schaffar G, Odoy S, Kahle PJ, 
Haass C, Kretzschmar H (2005) Single particle detection and 
characterization of synuclein co-aggregation. Biochem Biophys 
Res Commun 333:1202–1210. doi:10.1016/j.bbrc.2005.06.025 
(S0006-291X(05)01219-2 [pii])
 24. Gomori G (1942) A modification of the colorimetric phosphorus 
determination for use with the photoelectric colorimeter. J Lab 
Clin Med 27:955–960
 25. Gonzalez-Santamaria J, Campagna M, Ortega-Molina A, Marcos-
Villar L, de la Cruz-Herrera CF, Gonzalez D, Gallego P, Lopitz-
Otsoa F, Esteban M, Rodriguez MS et al (2012) Regulation of 
the tumor suppressor PTEN by SUMO. Cell Death Dis 3:e393. 
doi:10.1038/cddis.2012.135
 26. Gould SJ, Raposo G (2013) As we wait: coping with an imper-
fect nomenclature for extracellular vesicles. J Extracell Vesicles 
2. doi:10.3402/jev.v2i0.20389
 27. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, 
Outeiro TF, Melki R, Kallunki P, Fog K et al (2011) Alpha-Synu-
clein propagates from mouse brain to grafted dopaminergic neu-
rons and seeds aggregation in cultured human cells. J Clin Invest 
121:715–725. doi:10.1172/JCI43366
 28. Hasegawa T, Konno M, Baba T, Sugeno N, Kikuchi A, Kob-
ayashi M, Miura E, Tanaka N, Tamai K, Furukawa K et al (2011) 
The AAA-ATPase VPS4 regulates extracellular secretion and 
lysosomal targeting of alpha-synuclein. PLoS One 6:e29460. 
doi:10.1371/journal.pone.0029460
 29. Hecker CM, Rabiller M, Haglund K, Bayer P, Dikic I (2006) 
Specification of SUMO1- and SUMO2-interacting motifs. J Biol 
Chem 281:16117–16127. doi:10.1074/jbc.M512757200
 30. Henne WM, Buchkovich NJ, Emr SD (2011) The ESCRT path-
way. Dev Cell 21:77–91. doi:10.1016/j.devcel.2011.05.015
 31. Hogen T, Levin J, Schmidt F, Caruana M, Vassallo N, Kretzschmar 
H, Botzel K, Kamp F, Giese A (2012) Two different binding modes 
of alpha-synuclein to lipid vesicles depending on its aggregation 
state. Biophys J 102:1646–1655. doi:10.1016/j.bpj.2012.01.059
 32. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, Zhu C, Chen C, 
Liu X, Cheng J et al (2012) SUMO1 modification of PTEN regu-
lates tumorigenesis by controlling its association with the plasma 
membrane. Nat Commun 3:911. doi:10.1038/ncomms1919
 33. Jiang Z, Redfern RE, Isler Y, Ross AH, Gericke A (2014) Cho-
lesterol stabilizes fluid phosphoinositide domains. Chem Phys 
Lipids 182:52–61. doi:10.1016/j.chemphyslip.2014.02.003
 34. Karube H, Sakamoto M, Arawaka S, Hara S, Sato H, Ren CH, 
Goto S, Koyama S, Wada M, Kawanami T et al (2008) N-ter-
minal region of alpha-synuclein is essential for the fatty acid-
induced oligomerization of the molecules. FEBS Lett 582:3693–
3700. doi:10.1016/j.febslet.2008.10.001
 35. Knipscheer P, van Dijk WJ, Olsen JV, Mann M, Sixma TK (2007) 
Noncovalent interaction between Ubc9 and SUMO promotes 
SUMO chain formation. EMBO J 26:2797–2807. doi:10.1038/
sj.emboj.7601711
 36. Kordower JH, Brundin P (2009) Propagation of host disease to 
grafted neurons: accumulating evidence. Exp Neurol 220:224–
225. doi:10.1016/j.expneurol.2009.09.016
 37. Kramer-Albers EM, Gehrig-Burger K, Thiele C, Trotter J, Nave 
KA (2006) Perturbed interactions of mutant proteolipid protein/
DM20 with cholesterol and lipid rafts in oligodendroglia: impli-
cations for dysmyelination in spastic paraplegia. J Neurosci 
26:11743–11752. doi:10.1523/JNEUROSCI.3581-06.2006
 38. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao 
HH, Bossis G, Urlaub H, Zweckstetter M, Kugler S, Mel-
chior F et al (2011) Sumoylation inhibits alpha-synuclein 
aggregation and toxicity. J Cell Biol 194:49–60. doi:10.1083/
jcb.201010117
 39. Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollen-
hauer B (2012) Development of electrochemiluminescence-
based singleplex and multiplex assays for the quantification of 
alpha-synuclein and other proteins in cerebrospinal fluid. Meth-
ods 56:514–518. doi:10.1016/j.ymeth.2012.03.016
 40. Kugler S, Meyn L, Holzmuller H, Gerhardt E, Isenmann S, 
Schulz JB, Bahr M (2001) Neuron-specific expression of thera-
peutic proteins: evaluation of different cellular promoters in 
recombinant adenoviral vectors. Mol Cell Neurosci 17:78–96. 
doi:10.1006/mcne.2000.0929
 41. Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and 
exocytosis of alpha-synuclein and its aggregates. J Neurosci 
25:6016–6024. doi:10.1523/JNEUROSCI.0692-05.2005
713Acta Neuropathol (2015) 129:695–713 
1 3
 42. Lee Y, El Andaloussi S, Wood MJ (2012) Exosomes and 
microvesicles: extracellular vesicles for genetic information 
transfer and gene therapy. Hum Mol Genet 21:R125–R134. 
doi:10.1093/hmg/dds317
 43. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lash-
ley T, Quinn NP, Rehncrona S, Bjorklund A et al (2008) Lewy 
bodies in grafted neurons in subjects with Parkinson’s disease 
suggest host-to-graft disease propagation. Nat Med 14:501–503. 
doi:10.1038/nm1746
 44. Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski 
JQ, Lee VM (2012) Pathological alpha-synuclein transmission 
initiates Parkinson-like neurodegeneration in nontransgenic 
mice. Science 338:949–953. doi:10.1126/science.1227157
 45. Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM 
(2012) Intracerebral inoculation of pathological alpha-synuclein ini-
tiates a rapidly progressive neurodegenerative alpha-synucleinopa-
thy in mice. J Exp Med 209:975–986. doi:10.1084/jem.20112457
 46. Mathivanan S, Ji H, Tauro BJ, Chen YS, Simpson RJ (2012) 
Identifying mutated proteins secreted by colon cancer cell lines 
using mass spectrometry. J Proteomics 76(Spec No):141–149. 
doi:10.1016/j.jprot.2012.06.031
 47. Melchior F (2000) SUMO—nonclassical ubiquitin. Annu Rev 
Cell Dev Biol 16:591–626. doi:10.1146/annurev.cellbio.16.1.591
 48. Meulmeester E, Kunze M, Hsiao HH, Urlaub H, Melchior 
F (2008) Mechanism and consequences for paralog-specific 
sumoylation of ubiquitin-specific protease 25. Mol Cell 30:610–
619. doi:10.1016/j.molcel.2008.03.021
 49. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, 
Lakhdar L, Legastelois S, Baron T (2012) Prion-like acceleration 
of a synucleinopathy in a transgenic mouse model. Neurobiol 
Aging 33:2225–2228. doi:10.1016/j.neurobiolaging.2011.06.022
 50. Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M (2010) 
Seeded aggregation and toxicity of {alpha}-synuclein and tau: 
cellular models of neurodegenerative diseases. J Biol Chem 
285:34885–34898. doi:10.1074/jbc.M110.148460
 51. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Car-
valho F, Hyman BT, McLean PJ (2008) Formation of toxic oligo-
meric alpha-synuclein species in living cells. PLoS One 3:e1867. 
doi:10.1371/journal.pone.0001867
 52. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F (2002) 
The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 
108:109–120
 53. Pilla E, Moller U, Sauer G, Mattiroli F, Melchior F, Geiss-Fried-
lander R (2012) A novel SUMO1-specific interacting motif in dipep-
tidyl peptidase 9 (DPP9) that is important for enzymatic regulation. 
J Biol Chem 287:44320–44329. doi:10.1074/jbc.M112.397224
 54. Raiborg C, Rusten TE, Stenmark H (2003) Protein sorting into 
multivesicular endosomes. Curr Opin Cell Biol 15:446–455
 55. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade 
P, Simons K (2006) Alzheimer’s disease beta-amyloid peptides are 
released in association with exosomes. Proc Natl Acad Sci USA 
103:11172–11177. doi:10.1073/pnas.0603838103 (0603838103 [pii])
 56. Raposo G, Stoorvogel W (2013) Extracellular vesicles: 
exosomes, microvesicles, and friends. J Cell Biol 200:373–383. 
doi:10.1083/jcb.201211138
 57. Schneider A, Simons M (2013) Exosomes: vesicular carriers for 
intercellular communication in neurodegenerative disorders. Cell 
Tissue Res 352:33–47. doi:10.1007/s00441-012-1428-2
 58. Shen B, Wu N, Yang JM, Gould SJ (2011) Protein targeting to 
exosomes/microvesicles by plasma membrane anchors. J Biol 
Chem 286:14383–14395. doi:10.1074/jbc.M110.208660
 59. Shields SB, Piper RC (2011) How ubiquitin functions with ESCRTs. 
Traffic 12:1306–1317. doi:10.1111/j.1600-0854.2011.01242.x
 60. Shvadchak VV, Falomir-Lockhart LJ, Yushchenko DA, Jovin 
TM (2011) Specificity and kinetics of alpha-synuclein binding 
to model membranes determined with fluorescent excited state 
intramolecular proton transfer (ESIPT) probe. J Biol Chem 
286:13023–13032. doi:10.1074/jbc.M110.204776
 61. Simons M, Raposo G (2009) Exosomes–vesicular carriers for 
intercellular communication. Curr Opin Cell Biol 21:575–581. 
doi:10.1016/j.ceb.2009.03.007 (S0955-0674(09)00077-5 [pii])
 62. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert 
M (1998) Alpha-Synuclein in filamentous inclusions of Lewy 
bodies from Parkinson’s disease and dementia with lewy bodies. 
Proc Natl Acad Sci USA 95:6469–6473
 63. Stehmeier P, Muller S (2009) Phospho-regulated SUMO interac-
tion modules connect the SUMO system to CK2 signaling. Mol 
Cell 33:400–409. doi:10.1016/j.molcel.2009.01.013
 64. Stoorvogel W (2012) Functional transfer of microRNA by 
exosomes. Blood 119:646–648. doi:10.1182/blood-2011-11-389478
 65. Strauss K, Goebel C, Runz H, Mobius W, Weiss S, Feussner 
I, Simons M, Schneider A (2010) Exosome secretion amelio-
rates lysosomal storage of cholesterol in Niemann–Pick type 
C disease. J Biol Chem 285:26279–26288. doi:10.1074/jbc.
M110.134775 (M110.134775 [pii])
 66. Sun H, Leverson JD, Hunter T (2007) Conserved function of 
RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase 
to SUMOylated proteins. EMBO J 26:4102–4112. doi:10.1038/
sj.emboj.7601839
 67. Tauro BJ, Greening DW, Mathias RA, Mathivanan S, Ji H, Simp-
son RJ (2013) Two distinct populations of exosomes are released 
from LIM1863 colon carcinoma cell-derived organoids. Mol 
Cell Proteomics 12:587–598. doi:10.1074/mcp.M112.021303
 68. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland 
F, Schwille P, Brugger B, Simons M (2008) Ceramide triggers bud-
ding of exosome vesicles into multivesicular endosomes. Science 
319:1244–1247. doi:10.1126/science.1153124 (319/5867/1244 
[pii])
 69. Tsunemi T, Hamada K, Krainc D (2014) ATP13A2/PARK9 regu-
lates secretion of exosomes and alpha-Synuclein. J Neurosci 
34:15281–15287. doi:10.1523/JNEUROSCI.1629-14.2014
 70. Uchimura Y, Nakamura M, Sugasawa K, Nakao M, Saitoh H 
(2004) Overproduction of eukaryotic SUMO-1- and SUMO-
2-conjugated proteins in Escherichia coli. Anal Biochem 
331:204–206. doi:10.1016/j.ab.2004.04.034
 71. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO 
(2007) Exosome-mediated transfer of mRNAs and microRNAs 
is a novel mechanism of genetic exchange between cells. Nat 
Cell Biol 9:654–659. doi:10.1038/ncb1596
 72. van Meer G, Voelker DR, Feigenson GW (2008) Membrane 
lipids: where they are and how they behave. Nat Rev Mol Cell 
Biol 9:112–124. doi:10.1038/nrm2330
 73. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Cabo F, 
Perez-Hernandez D, Vazquez J, Martin-Cofreces N, Martinez-
Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sanchez-
Madrid F (2013) Sumoylated hnRNPA2B1 controls the sorting 
of miRNAs into exosomes through binding to specific motifs. 
Nat Commun 4:2980. doi:10.1038/ncomms3980
 74. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, 
Stieber A, Meaney DF, Trojanowski JQ, Lee VM (2011) Exog-
enous alpha-synuclein fibrils induce Lewy body pathology lead-
ing to synaptic dysfunction and neuron death. Neuron 72:57–71. 
doi:10.1016/j.neuron.2011.08.033
 75. Zhu J, Zhu S, Guzzo CM, Ellis NA, Sung KS, Choi CY, Matu-
nis MJ (2008) Small ubiquitin-related modifier (SUMO) binding 
determines substrate recognition and paralog-selective SUMO 
modification. J Biol Chem 283:29405–29415. doi:10.1074/jbc.
M803632200
